LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

299.28 -1.65

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

296.67

Max

299.28

Schlüsselkennzahlen
By Trading Economics
Einkommen	4.5M 56M
Verkäufe	9.3M 116M
KGV Branchendurchschnitt	39.115 49.701
EPS	1.83
Gewinnspanne	48.069
Angestellte	295
EBITDA	16M 55M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+7.53% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	585M 8.6B
Vorheriger Eröffnungskurs	300.93
Vorheriger Schlusskurs	299.28

Nachrichtenstimmung

By Acuity

22%

78%

34 / 345 Ranking in Healthcare

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Mai 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24. Mai 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24. Mai 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24. Mai 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24. Mai 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24. Mai 2026, 22:26 UTC

Akquisitionen, Fusionen, Übernahmen

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24. Mai 2026, 22:25 UTC

Akquisitionen, Fusionen, Übernahmen

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24. Mai 2026, 22:25 UTC

Akquisitionen, Fusionen, Übernahmen

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24. Mai 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24. Mai 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24. Mai 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24. Mai 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24. Mai 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24. Mai 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23. Mai 2026, 08:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

23. Mai 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. Mai 2026, 21:10 UTC

Ergebnisse

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22. Mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. Mai 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

22. Mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. Mai 2026, 19:47 UTC

Ergebnisse

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22. Mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22. Mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22. Mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22. Mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22. Mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22. Mai 2026, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22. Mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22. Mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

7.53% Vorteil

12-Monats-Prognose

Durchschnitt 322 USD 7.53%

Hoch 378 USD

Tief 284 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Stimmung

By Acuity

34 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.